LB Pharma’s Novel Antipsychotic LB-102 Shows Promising Phase II Results for Schizophrenia
LB-102 is a once-daily oral antipsychotic being developed as a potential first-in-class benzamide for treating schizophrenia in the US
The Phase II trial (NOVA1) met its primary endpoint, showing statistically significant reduction in PANSS scores compared to placebo at all dose levels tested
359 patients with acute schizophrenia were enrolled in the trial
The 50 mg dose showed a 5.0-point reduction in PANSS score vs placebo (p=0.0009)
LB-102 was generally safe and well-tolerated, with low incidence of common antipsychotic side effects
Results support advancing LB-102 to Phase III clinical development
If approved, LB-102 would be the first benzamide antipsychotic available in the US market
The positive data suggests potential for reviving the benzamide class of antipsychotics, which has been dormant in the US
LB Pharma plans to explore LB-102 for additional psychiatric indications and develop a long-acting injectable formulation
The trial results indicate LB-102 could potentially offer a new treatment option for schizophrenia patients in the US, with a favorable efficacy and safety profile compared to existing antipsychotics. This represents a potential revival of the benzamide antipsychotic class that has not been available to US patients previously.